Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Frontiers in Immunology|February 20, 2019
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary ImmunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.Immunotherapy|August 9, 2018
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseasesHans D Ochs, Isaac Melamed, Michael Borte, et al.Frontiers in Immunology|January 6, 2023
Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Sudhir Gupta, Isaac Melamed, et al.Journal of Clinical Immunology|March 23, 2011
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency diseaseRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.Neurology(R) Neuroimmunology & Neuroinflammation|October 24, 2014
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033Jonathan Q Tran, Jitesh Rana, Frederik Barkhof, et al.Journal of Clinical Immunology|March 7, 2012
Safety, efficacy and pharmacokinetics of a new 10% liquid intravenous immunoglobulin (IVIG) in patients with primary immunodeficiencyRichard L Wasserman, Joseph A Church, Mark Stein, et al.Clinical and Experimental Immunology|October 8, 2022
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficienciesRoger H Kobayashi, Jiří Litzman, Isaac Melamed, et al.Journal of Clinical Immunology|May 9, 2023
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion RegimensSudhir Gupta, James DeAngelo, Isaac Melamed, et al.Journal of Clinical Immunology|May 26, 2016
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary ImmunodeficiencyRichard L Wasserman, Isaac Melamed, Mark R Stein, et al.Journal of Neuroimmunology|December 30, 2019
Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptomsCraig Shimasaki, Richard E Frye, Rosario Trifiletti, et al.Pageof 4